Dataset for: Cost per Detection of Amyloidosis with Routine Tenosynovial Biopsy During Carpal Tunnel Release: A Literature-Based Subgroup Analysis
Description
This dataset supports a literature-based cost analysis evaluating the economic efficiency of tenosynovial biopsy performed during carpal tunnel release (CTR) as a screening strategy for amyloidosis. The study hypothesis was that cost per detected case of amyloidosis would vary substantially according to disease prevalence and would be lower in clinically defined higher-risk patient populations than in unselected CTR populations. The dataset was assembled from published literature and publicly available cost sources. It includes amyloid prevalence estimates reported in CTR populations and higher-risk subgroups, procedural and pathology cost estimates, operative time data obtained from a retrospective series of CTR procedures, and operating room cost assumptions for clinic, ambulatory surgery center, and hospital settings. Derived variables include the number needed to biopsy (NNB), calculated as the inverse of prevalence, and cost per detected case of amyloidosis. The data demonstrate that cost per detected case is highly dependent on underlying disease prevalence. Cost per detected case was substantially higher in general CTR populations and markedly lower in higher-risk subgroups, where NNB approached one. These findings suggest that a risk-stratified biopsy strategy may be more economically efficient than universal biopsy during CTR. The dataset can be used to reproduce the study analyses, evaluate the impact of alternative prevalence or cost assumptions, and inform future investigations of screening strategies for amyloidosis in hand surgery populations. Variables should be interpreted as model inputs and outputs derived from published estimates rather than patient-level clinical data.
Files
Institutions
- University of Colorado Anschutz Medical CampusColorado, Aurora